Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

NCT00742716 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Secondary Hyperparathyroidism
Chronic Renal Insufficiency
Chronic Renal Failure

Interventions

DRUG: CTA018 Injection

Sponsor

OPKO IP Holdings II, Inc.